Trial Profile

A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours
Focus Registrational; Therapeutic Use
Acronyms RADIANT-4
Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation

15 Apr 2021 Results of post hoc pooled analysis from RADIANT-3 and RADIANT-4, published in the Cancer.
13 Sep 2020 This trial is completed in Austria (Global End Date: 07 Aug 2020), according to European Clinical Trials Database record.
01 Sep 2020 This trial has been completed in Poland.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com